<DOC>
	<DOCNO>NCT01076010</DOCNO>
	<brief_summary>Open-label , multi-center extension treatment protocol allow access tivozanib sorafenib subject participate AV-951-09-301 protocol . Eligible subject randomize receive sorafenib AV-951-09-301 document progression disease receive tivozanib dose 1.5 mg/day . Eligible subject randomize tivozanib sorafenib AV-951-09-301 , display clinical benefit acceptable tolerability treatment , continue receive tivozanib sorafenib dose schedule AV-951-09-301 .</brief_summary>
	<brief_title>An Extension Treatment Protocol Subjects Who Have Participated Phase 3 Study Tivozanib Versus Sorafenib Renal Cell Carcinoma ( Protocol AV-951-09-301 )</brief_title>
	<detailed_description>This extension treatment protocol allow access tivozanib sorafenib subject enrol AV-951-09-301 ( parent protocol ) . Subjects fail sorafenib parent protocol offer tivozanib . Subjects randomize tivozanib , demonstrate clinical benefit acceptable tolerability offer long-term access tivozanib . Subjects randomize sorafenib , demonstrate clinical benefit acceptable tolerability offer long-term access sorafenib . Subjects continue receive sorafenib protocol progress allow cross-over tivozanib .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . The subject must participate Protocol AV95109301 , must meet either follow bulleted criterion : Demonstrated disease progression per RECIST treatment sorafenib , OR Demonstrated clinical benefit [ complete response ( CR ) , partial response ( PR ) , stable disease ( SD ) per RECIST ] acceptable tolerability treatment tivozanib sorafenib protocol AV95109301 2 . ECOG performance status ≤ 2 ( see Appendix C ) life expectancy ≥ 3 month . 3 . If female childbearing potential , documentation negative pregnancy test prior enrollment . 4 . Ability give write informed consent 1 . Newly identify CNS malignancy document progression CNS metastases ; subject allow CNS metastasis adequately treat radiotherapy surgery . For subject receive steroid therapy please refer Section 6.3 allow steroid maintenance therapy 2 . Duration since last dose Protocol AV95109301 : 1 . For subject continue tivozanib sorafenib ( subject demonstrate clinical benefit acceptable tolerability treatment tivozanib sorafenib protocol AV95109301 ) : 2 week since last dose tivozanib sorafenib 2 . For subject initiate tivozanib ( ie demonstrate disease progression treatment sorafenib ) : 4 week since last dose sorafenib . Subjects demonstrate disease progression due CNS metastasis allow 8 week since last dose sorafenib order complete treatment CNS metastasis 3 . Inadequate recovery prior surgical procedure major surgical procedure within 4 week prior administration first dose study drug 4 . Any following hematologic abnormality : Hemoglobin &lt; 9.0 g/dL ANC &lt; 1500 per mm3 Platelet count &lt; 75,000 per mm3 PT PTT &gt; 1.5 × ULN 5 . Any following serum chemistry abnormality : Total bilirubin &gt; 1.5 × ULN ( &gt; 2.5 × ULN subject Gilbert 's syndrome ) AST ALT &gt; 2.5 × ULN ( &gt; 5 × ULN subject liver metastasis ) Alkaline phosphatase &gt; 2.5 × ULN ( &gt; 5 × ULN subject liver bone metastasis ) Creatinine &gt; 2.0 × ULN Proteinuria &gt; 3+ urinalysis urine dipstick 6 . If female , pregnant lactate 7 . Sexually active premenopausal female subject ( female partner male subject ) must use adequate contraceptive measure , study least 50 day last dose study drug . Sexually active male subject must use adequate contraceptive measure , study least 90 day last dose study drug . All fertile male female subject , partner , must agree use highly effective method contraception . Effective birth control include ( ) IUD plus one barrier method ; ( b ) 2 barrier method . Effective barrier method male female condom , diaphragm , spermicide ( creams gel contain chemical kill sperm ) . ( Note : Oral , implantable , injectable contraceptive may affect cytochrome P450 interaction , consider effective study . ) 8 . Uncontrolled hypertension : systolic blood pressure &gt; 150 mmHg diastolic blood pressure &gt; 100 mmHg 2 antihypertensive medication , document 2 consecutive measurement take least 24 hour apart . 9 . Unhealed wound ( include active peptic ulcer ) 10 . Serious/active infection infection require parenteral antibiotic 11 . Lifethreatening illness organ system dysfunction compromise safety evaluation 12 . Psychiatric disorder , alter mental status precluding inform consent necessary test 13 . Inability comply protocol requirement 14 . Treatment another anticancer therapy participation another interventional protocol ( exclude AV95109301 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>